|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
Despite a slight difference persisting in the meta-analysis carried out using four European populations, these data suggest, altogether, that UHMK1 does not play a major role in susceptibility to schizophrenia.
|
21399567 |
2011 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Despite a slight difference persisting in the meta-analysis carried out using four European populations, these data suggest, altogether, that UHMK1 does not play a major role in susceptibility to schizophrenia.
|
21399567 |
2011 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
For comparison we have analyzed PAX-5 expression in another B-cell lymphoma, KIS-1, indicating that transcription from the distal PAX-5 promoter was increased in this tumor in agreement with the previously characterized translocation of the immunoglobulin Emicro; enhancer adjacent to PAX-5 exon 1A.
|
9808580 |
1998 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further, in vivo KIS gene silencing enhanced the antitumor activity of erlotinib in an orthotopic breast cancer xenograft model.
|
21045138 |
2010 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further, in vivo KIS gene silencing enhanced the antitumor activity of erlotinib in an orthotopic breast cancer xenograft model.
|
21045138 |
2010 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Hence, these data do not provide support for the hypothesis that altered expression is the mechanism by which genetic variation of KIS may increase susceptibility to schizophrenia, nor evidence that KIS expression is altered in the disease itself, at least in terms of the parameters studied here.
|
19747464 |
2009 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Hence, these data do not provide support for the hypothesis that altered expression is the mechanism by which genetic variation of KIS may increase susceptibility to schizophrenia, nor evidence that KIS expression is altered in the disease itself, at least in terms of the parameters studied here.
|
19747464 |
2009 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of miR-148a-5p targets (PHLDA2, LPCAT2 and AP1S3) and miR-148a-3p targets (SMA, ENDOD1 and UHMK1) was associated with poor prognosis of patients with PDAC.
|
29660218 |
2018 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells.
|
18384876 |
2008 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Like YAP, UHMK1 stimulates nuclear enrichment of MYBL2, which is associated HCC cell proliferation and the expression of the cell cycle regulators CCNB1, CCNB2, KIF20A, and MAD2L1.
|
30936457 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Moreover, we found that KIS protein was overexpressed in all 132 adults cases of various leukemias, including 37 AML (8 M1, 12 M2, 2 M3, 7 M4, 8 M5), 72 MDS (42 RAEB-I, 30 REAB-II) and 23 ALL (23 L2).
|
18384876 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Moreover, we found that KIS protein was overexpressed in all 132 adults cases of various leukemias, including 37 AML (8 M1, 12 M2, 2 M3, 7 M4, 8 M5), 72 MDS (42 RAEB-I, 30 REAB-II) and 23 ALL (23 L2).
|
18384876 |
2008 |
|
Schizophrenia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Of these, four contained or neighboured genes associated with schizophrenia (NOS1AP/UHMK1, ATF2, NSF and PIK3C3).
|
19451863 |
2009 |
|
Plexiform Neurofibroma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
On the other hand, the KIS gene was overexpressed in NF1-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs) as compared to dermal neurofibroma which suggests a possible implication of KIS in the genesis of NF1-associated tumors.
|
12782393 |
2003 |